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SynchronizationtBid is a pro-apoptotic molecule. Apoptosis inducers usually act in a cell cycle-speciﬁc fashion. The aim of this
study was to elucidate whether effect of tBid on hepatocellular carcinoma (HCC) Hep3B cells was cell cycle
phase speciﬁc. We synchronized Hep3B cells at G0/G1, S or G2/M phases by chemicals or ﬂow sorting and
tested the susceptibility of the cells to recombinant tBid. Cell viability was measured by MTT assay and
apoptosis by TUNEL. The results revealed that tBid primarily targeted the cells at G0/G1 phase of cell cycle, and
it also increased the cells at the G2/M phase. 5-Fluorouracil (5-FU), on the other hand, arrested Hep3B cells at
the G0/G1 phase, but signiﬁcantly reduced cells at G2/M phase. The levels of cell cycle-related proteins and
caspases were altered in line with the change in the cell cycle. The combination of tBid with 5-FU caused more
cells to be apoptotic than either agent alone. Therefore, the complementary effect of tBid and 5-FU on different
phases of the cell cycle may explain their synergistric effect on Hep3B cells. The elucidation of the phase-
speciﬁc effect of tBid points to a possible therapeutic option that combines different phase speciﬁc agents to
overcome resistance of HCC.Wales Hospital, Shatin, New
2 2645 0605.
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
It iswell established thatmanywidely used apoptosis inducers act in
a cell cycle-speciﬁc fashion [1,2]. For example, studies have found that
Doxorubicin predominantly induced G2/M arrest [3,4], while 5-
ﬂuorouracil (5-FU) induced G1, S phase arrest depending on the types
of tumor cells [5,6].
Bid, the BH3-only pro-apoptotic Bcl-2 family member, is predom-
inantly deﬁned by its pro-death activity. Its activated form caspase-
truncated Bid (tBid) activates Bax and Bak, which are required for the
release of cytochrome c from mitochondria and the downstream
apoptotic program. Bid/tBid connects the death receptor apoptosis
pathway to the mitochondrial apoptosis pathway [7], and their
expression is closely associated with the sensitivity of hepatocellular
carcinoma (HCC) cells to chemotherapeutic drugs [8,9].
Bcl-2 family members have various roles in DNA damage and cell
cycle control [10]. Studies have also outlined that Bid is involved in
maintaining genomic stability and integrating the control of apopto-
sis, cell cycle arrest, and DNA repair [11–13]. Bid is phosphorylated in
the nucleus and plays a role in cell cycle checkpoint control. Bid-
deﬁcient mice are known to be resistant to Fas-induced hepatocellular
apoptosis [14]. Following treatment with aphidicolin, Bid(+/+) but
not Bid(−/−) myeloid precursor cells (MPCs) arrest and accumulate
in S phase [12]. A recent study in HCC cells showed that Bid exhibited
dual functions of S phase arrest and sensitization to apoptosis inresponse to different degrees of etoposide-induced DNA damage [15].
However, a conﬂicting result showed that Bid had no role in DNA
damage- or replicative stress-induced apoptosis or cell cycle arrest in
Bid-deﬁcient mice [16].
The objective of this study was to test the susceptibility of HCC
Hep3B cells in deﬁned phases of cell cycle to tBid. We synchronized
Hep3B cells at deﬁned cell phases and tested the susceptibility of
Hep3B cells at G0/G1, S or G2/M phases to tBid. The results
demonstrated that in contrast to 5-FU that arrested Hep3B cells in
the G0/G1 phase and signiﬁcantly reduced cells in G2/M phase, tBid
signiﬁcantly reduced Hep3B cells in G0/G1 phase and caused cells
arrest in G2/M phase. The elucidation of phase-speciﬁc effect of tBid
may point to a possible therapeutic option that combines different
phase-speciﬁc agents to treat HCC.
2. Materials and methods
2.1. Cell culture and cell viability assay
The human HCC cell line Hep3B was obtained from American Type
Culture Collection (Rockville, MD) and maintained in Dulbecco's
modiﬁed Eagle medium (Invitrogen, Carlsbad, CA) supplemented
with 10% heat-inactivated fetal bovine serum at 37 °C with 5% CO2.
Cell viability was assessed by MTT assay [8].
2.2. Expression and puriﬁcation of recombinant protein
Human tBid gene was cloned into a modiﬁed pGEX-6P-3 vector (GE
Medical Systems, Little Chalfont, UK), which allows the expression of
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(GST) tag. The complete sequence of the N-terminal tag was
“CTGGAAGTTCTGTTCCAGGGGCCC” in single-letter code. The nucleotide
sequenceswere veriﬁed by sequencing the entire gene. The tBid protein
was expressed and puriﬁed according to the GST gene fusion system
handbook (Amersham Biosciences). Brieﬂy, the GST fusion protein of
tBid was expressed in Escherichia coli BL21 and puriﬁed from the cell
extracts by afﬁnity chromatography on Glutathione Sepharose 4B
column (GEMedical Systems, Little Chalfont, UK). The separation of the
recombinant protein from the GST moiety was accomplished by site-
speciﬁc proteolysis using PreScission™ Protease (GE Medical Systems,
Little Chalfont, UK). Proteins were stored at−20 °C in 50 mM Tris–HCl
buffer (pH 8.0). The tBid protein with N-terminal Flag tag (Flag-tBid)
was also produced using the pGEX-6P-3 expression system. Protein
concentrations were determined by Bradford assay with Coomassie
Brilliant Blue G-250 dye (Bio-Rad) using bovine serum albumin as a
standard [17].
2.3. In vitro cytochrome c release assay
The biological activity of tBid proteins was determined by the
cytochrome c release assay from isolated Hep3B cell mitochondria
[18]. Mitochondria were isolated at 4 °C according to the instruction of
themitochondria isolation kit for cultured cells (Pierce Biotechnology,
Rockford, IL). Enriched mitochondria were used in the cytochrome c
release assay. The half maximal effective concentration (EC50) for
cytochrome c releasing was quantiﬁed by using human cytochrome c
ELISA Module Set (Bender MedSystems, Inc., CA).
2.4. Cell cycle analysis
Cell cycle analysis by ﬂow cytometry was performed by detaching
cells from culture plates with trypsin, washing twice with PBS and
ﬁxing in 75% ethanol–PBS. After keeping cells in ﬁxative overnight at
4 °C, cells were centrifuged for 5 min at 3000×g. The cell pellet was
resuspended and incubated for 30 min in 0.05 mg/ml PI, 1 mM EDTA,
0.1% Triton X-100, and 1 mg/ml RNAse A in PBS for 30 min at room
temperature. The suspension was then analyzed on a Becton
Dickinson FACScan. The ratio of cells in the G0/G1, S, and G2/M
phases of cell cycle was determined by their DNA content.
2.5. Western blot analysis
Cells were lysed in RIPA buffer containing protease inhibitors
(0.1 mg/ml PMSF, 30-fold diluted aprotinin and 1 mM sodium
orthovanadate). The protein extracts (20 μg) were electrophoresed
on 12% SDS-PAGE gels and transferred onto Hybond membranes
(Amersham Biosciences, Buckinghamshire, UK) by electroblotting at
100 V for 2 h. The membranes were blocked in 5% nonfat milk and
then were incubated with the designated primary antibodies at 4 °C
overnight, followed by incubation with a HRP-conjugated secondary
antibody for another hour. After themembranewaswashedwith Tris-
buffered saline containing Tween-20, the reaction was visualized by
means of the ECL reagent kit (Amersham Biosciences). The membrane
was exposed to X-ray ﬁlms. The antibody against Bid was obtained
from Becton Dickinson Pharmingen (Rockville, MD). The antibody
against Flag was obtained from Sigma (St. Louis, MO). The antibodies
against caspase-9, caspase-3, cdc2 p34, p-cdc2 p34 (Tyr 15), cyclin A,
cyclin B1 were obtained from Cell signaling (Danvers, MA). The
antibody against cyclin D1 was obtained from Abcam (Cambridge,
UK). The antibody against cyclin-dependent kinase 2 (Cdk2) was
obtained from Chemicon (Billerica, MA). The antibodies against p-
cdc2 p34 (Thr 161) and actin were obtained from Santa Cruz (Santa
Cruz, CA). Densitometry was performed using the Quantity One
imaging system 4.6.2 (Bio-Rad).2.6. Assessment of apoptosis by TUNEL assay
APO- BRDU™ Flow cytometry kit for apoptosis (Phoenix Flow
Systems, San Diego, CA) was employed. Cells incubated with tBid
were harvested by trypsinization. The cells were afterwards washed,
resuspended, ﬁxed, and stained in staining solution, which was a
mixture of TdT reaction buffer, TdT enzyme, Br-dUTP, and distilled
water for 60 min at 37 °C in a temperature-controlled bath and were
shaken every 15 min. After staining, cells were washed with 1 ml
rinse buffer for two times. Br-dUTP-labeled DNA breaks in apoptotic
cells can be detected by ﬂow cytometry. Apoptosis was measured
according to the protocol provided by the kit, and the results were
presented as percentage of apoptotic cells.
2.7. Synchronization of Hep3B cells at deﬁned cell cycles
Synchronization of the cells at deﬁned cell cycles was achieved by
chemicals [19,20] or ﬂuorescence-activated cell sorter (FACS). For the
chemicals-mediated synchronization, Hep3B cells were synchronized
at G0/G1 phase by incubation in serum-free medium for 48 h. Cells in
serum-free medium were synchronized at S phase by two methods.
Method one, cells were incubated with 0.2 μg/ml aphidicolin (AP, MP
Biomedicals, LLC, Santa Ana, CA) for 24 h and released in DMEM plus
10% FBS for 1 h. Method two, cells were incubated with 0.5 mM
hydroxyurea (HY, MP Biomedicals, LLC, Santa Ana, CA) for 12 h and
released in DMEM plus 10% FBS for 6 h. Cells in serum-free medium
were synchronized at G2/M phase by 0.2 μM etoposide (ET, MP
Biomedicals, LLC, Santa Ana, CA) for 24 h. Synchronization was
conﬁrmed by PI staining and ﬂow cytometry (see above). The
concentrations of AP, HY, and ET were found to be without discernible
biological effect on Hep3B cells, as cell viabilities after release from
block were routinely over 95%. Synchronized cells were used for
experimentation immediately to prevent cells from reentering the cell
cycle.
To synchronize the cells by FACS, the human Hep3B cells were
transiently transfected with a cDNA encoding Histone H2B and green
ﬂuorescentprotein (H2B-GFP) (Pharmingen)using the Lipofectamine™
2000 (Invitrogen, Carlsbad, CA) and selected in blasticidin (1 μg/ml, MP
Biomedicals, LLC, Santa Ana, CA). H2B-GFP stable Hep3B cell line was
obtained. FACS puriﬁcation of cells with deﬁned chromatin content was
based on their H2B-GFP-dependent ﬂuorescence (FL1, DNA content)
and forward scatter characteristics (FSC, size) [21].
2.8. Cell phase-speciﬁc effect of tBid on synchronized Hep3B cells
The effect of tBid on synchronized Hep3B cells was reﬂected by the
changes in cell cycle progression, cell cycle protein expression, and
cell viability. To determine the effect of tBid on cell cycle progression
and cell cycle protein expression, synchronous (at G0/G1, S, and G2/M
phase) or asynchronous Hep3B cells were exposed to 200 nM tBid.
The working concentration of tBid was calculated based on the typical
EC50 for cytochrome c releasing. The cell cycle progression was
monitored for 24 h. At 0, 8, 16, and 24 h, aliquots of cultured cells were
sampled for ﬂow cytometric analysis and Western blot analysis. To
assess the effect of tBid on cell viability, the synchronous or
asynchronous Hep3B cells were exposed to 200 nM tBid at 37 °C for
24 or 48 h. Then cell viability was determined based on the reduction
of MTT dye as previously described [8].
2.9. Cell phase-speciﬁc effect of 5-FU
Hep3B cells (3×105 cells in 2 ml per well) were plated in 6-well
plates and allowed to grow overnight. Then the cells were treated
with 20 μg/ml and 50 μg/ml of 5-FU for 12 h, 24, 36, and 48 h at 37 °C
with 5% CO2 before they were collected for cell cycle analysis by ﬂow
cytometry.
Fig. 2. Effects of cell phase synchronization agents on Hep3B cells. Cell cycle distribution
of Hep3B cells that were subjected to chemical synchronization. The percentage of cells
in the G0/G1, G2/M, and S phases of the cell cycle was determined by the DNA content.
Data are mean±SE of three independent experiments.
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The differences in the mean of the values between groups were
compared for statistical signiﬁcance using the Student's t-test by SPSS
15.0. pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. Activity of recombinant tBid
To assess whether puriﬁed recombinant tBid proteins were
correctly folded and functional, we analyzed the cytochrome c release
from the isolated Hep3Bmitochondria in response to tBid stimulation.
The EC50 for tBid to release cytochrome c was 200.6 nM (Fig. 1A).
The inhibitory activity of the isolated tBid protein on cell growth
was also determined by MTT colorimetric assay. Recombinant tBid
inhibited growth of Hep3B cells in concentration- and time-Fig. 1. Effect of tBid on Hep3B cells. A, Cytochrome c release from the isolated mitochondria of Hep3B cells in response to tBid. B, Effect of tBid on the viability of Hep3B cells. Hep3B
cells were cultured in 96-well plates and treated with different concentrations of tBid for 24, 48, and 72 h (24 h: solid square, 48 h: open square, 72 h: open triangle) at 37 °C. The
viability of cells was expressed as a relative value to that of cells treated with vehicle. Data are the mean±SE of four separate experiments. C, Effect of tBid on apoptosis of Hep3B
cells. Cells were treated with 200 nM tBid for 24 h. Apoptosis was assayed by TUNEL using ﬂow cytometry. The proportion of the apoptotic cells was shown. The cells treated with
vehicle were served as control. Data are themean±SE of three separate experiments. **Indicates pb0.01. D,Western blot analysis of the level of tBid. Cells were treated with 50, 100,
and 200 nM tBid for 24 h. Total protein was isolated after treatment andWestern blot was used to detect tBid expression. Actin level was examined and served as the loading control.
Experiments were repeated twice. Bar graphs show tBid expression normalized to actin (mean±SE, *pb0.05 and **pb0.01 vs. control). E, Western blots prepared from whole-cell
extracts of Hep3B cells treated with 200 nM Flag-tBid protein for 24 and 48 h. (Upper band) Western blot incubated with anti-Bid. The expected 16-kDa band is present in the cell
extract. (Middle band) The same 16-kDa band is recognized by anti-Flag, while no band is recognized by this antibody in the control cells. Bar graphs show protein expression
normalized to actin (mean±SE, *pb0.05 and **pb0.01 vs. control). F, Western blot analysis of the level of cytosolic cytochrome c. Cells were treated with tBid for 24 h. Cytosolic
protein was isolated after treatment andWestern blot was used to detect cytochrome c level. Actin level was examined and served as the loading control. Experiments were repeated
twice.
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corresponded to the cytosolic level of cytochrome c induced by tBid
(Fig. 1F). The ﬁnding is in line with other reports showing that the
amount of cytochrome c release was proportional to tBid treatment
[22–24]. Consistent with the inhibition of cell growth, apoptosis
determined after 24-h tBid treatment was increased in Hep3B cells
(Fig. 1C). In order to determine the efﬁciency of the recombinant tBid
entering the Hep3B cells, two experiments were arranged. Firstly, we
determined the dose-dependent change in tBid protein expression
after the cells were treated with recombinant tBid. Secondly, we used
Flag-labeling recombinant tBid to show that the Flag was increased in
the same manner as tBid in the cells. In the ﬁrst experiment, the level
of tBid was increased in Hep3B cells after treatment by differentFig. 3. Cell cycle proﬁles andprotein expression in asynchronousand synchronousHep3Bcells e
by ET as described in Materials and methods. Then cells were treated with 200 nM tBid or veh
three separate experiments. B,Cell cycle-relatedproteins, caspase9 andcaspase 3expression.At i
p-Cdc2 p34 (Thr 161), caspase 9 and caspase 3 at each time point were analyzed with Westernconcentrations of tBid for 24 h (Fig. 1D). In the second experiment,
Western blot analysis using anti-Flag antibody detected the same
band as anti-Bid antibody in whole-cell extracts of Hep3B cells treated
with a Flag–tBid protein and the protein band identiﬁedwith anti-Flag
was increased in the similar fashion to that detected by anti-tBid at 24
and 48 h (Fig. 1E).
3.2. Cell synchronization
Cell synchronization by serum starvation and chemicals accumulated
more than 60% of cells in G0/G1 phase, 75% (by AP) and 60% (by HY) in S
phase, 70% inG2/Mphase (Fig. 2). As shown in supplementary Fig. S1, these
methods did not signiﬁcantly damage the cells. However, chemicalxposed to tBid. Hep3B cellswere synchronized at S phase byeitherAPorHY, atG2/Mphase
icle as control. A, Flow cytometric analysis of cell cycle progression. Data are mean±SE of
ndicated timepoints, aliquots of cellswere sampled, the levelsof Cdk2, p-Cdc2p34(Tyr15),
blot analysis. Actin level was examined and served as the loading control.
Fig. 3 (continued).
Fig. 4. Susceptibility of the phase-synchronized Hep3B cells to tBid-mediated cell death.
Cell viability was determined based on the reduction of MTT dye. The inhibitory effects
were expressed as 100%minus the survival percentage of treated cells versus control cells.
A, Hep3B cells at G0/G1, S and G2/Mphases of cell cyclewere treatedwith 200 nM tBid for
48 h. Data aremean±SE of three independent experiments. *Indicates pb0.05, compared
with eachof the rest 4 columns.B, TheG1phase synchronizedHep3B-GFPcells obtainedby
ﬂowsorting as described in Fig. 4were treatedwith 200 nMtBid for 24 h. Total Hep3B-GFP
cells treated with vehicle were use as control. Data are mean±SE of three independent
experiments. **Indicates pb0.01.
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activate cell cycle checkpoint mechanisms and that sometimes they were
rather toxic. We therefore employed ﬂow sorting method to conﬁrm the
result obtained by chemical-based cell synchronization. In the ﬂow sorting
method, we generated Hep3B cells that stably express H2B–GFP fusion
proteins as a stoichiometric probeofDNAcontent, thus by FACSpuriﬁcation,
we could obtain the unmanipulated, non-synchronized G1 population that
was suitable for the study of the impact of cell cycle on apoptosis regulation.
3.3. Cell phase-speciﬁc effect of tBid
To determine whether tBid speciﬁcally or preferably targets a
given phase of the cell cycle, Hep3B cells were synchronized at
deﬁned cell phases by serum starvation, chemical synchronization,
and ﬂow sorting, followed by tBid treatment. For analyses of cell cycle
proﬁles and the expression of caspase and cell cycle-related proteins,
synchronous (at G0/G1, S and G2/M phase) or asynchronous Hep3B
cells were exposed to 200 nM tBid. At the indicated times, aliquots of
the cultured cells were sampled for ﬂow cytometric analysis and
protein was extracted for Western blot analysis. The percentages of
phase fractions were shown in Fig. 3A. Results showed that treatment
with tBid increased the Hep3B cell in G2/M phase of cell cycle, which
was accompanied by the reduction of cells in the G0/G1 phase. The
percentage of G0/G1 phase fraction in tBid-treated cells was
statistically less than that in control non-treated cells (Fig. 3A,
pb0.05), indicating that cells in the G0/G1 phase were particularly
targeted by tBid. In addition to the effect of tBid on cell cycle
progression, Western blot analysis results showed that tBid decreased
the levels of Cdk2 and p-cdc2 p34 (Tyr 15) but increased the level of
p-cdc2 p34 (Thr 161), compared with the control cells (Fig. 3B).
However, tBid did not signiﬁcantly affect the levels of cdc2 p34, cyclin
A, cyclin D1, and cyclin B1 (Fig. S2). The expression of procaspase 9,
cleaved caspase 9, and caspase 3 was signiﬁcantly increased in cells
treated by tBid compared with the control cells (Fig. 3B and Fig. S3).
To assess the sensitivity of the synchronized cells to tBid
treatment, cell viability was assayed by MTT assay to reﬂect the
percentage of cell death. As shown in Fig. 4A, synchronization with
serum starvation at G0/G1 phase resulted in an inhibitory rate of 31%
by tBid, compared to 16–24% in the asynchronous counterparts or
cells synchronized at other phases of the cell cycle. The high
sensitivity of the G1 phase cells synchronized by serum starvation
was conﬁrmed in the cells synchronized at the G1 phase by ﬂow
sorting (Fig. 4B). The G1-enriched Hep3B-GFP cells showed a
signiﬁcant increase in the vulnerability to tBid-mediated cell death
compared to the asynchronous population. These results conﬁrmed
the cell cycle profile result that showed that tBid wasmore effective in
targeting cells at G0/G1 phase (Fig. 3A). Collectively, the data
indicated that Hep3B cells at G0/G1 phase were relatively more
susceptible to tBid-mediated cell death.3.4. Cell phase-speciﬁc effect of 5-FU
Most chemotherapeutic agents play roles in anti-growth of cancer
cells with variations of cytotoxic effects in the cell cycles. 5-FU may act
throughout all phases of the cell cycle or at some speciﬁc phases of the
cell cycle depending on the types of cells [5,6]. As shown in Fig. 5A andB,
20 μg/ml and 50 μg/ml 5-FU arrested Hep3B cells in the G0/G1 phase,
signiﬁcantly reduced cells in the G2/M phase since 12 h after treatment.3.5. Effect of tBid in combination with 5-FU on Hep3B cells
As shown in Fig. 6A, 200 nM tBid in combinationwith 50 μg/ml 5-FU
causedmore Hep3B cells to be apoptotic than either agent alone. In line
with the increase in apoptotic cells, the level of tBid was elevated
accordingly (Fig. 6B).
Fig. 5. Cell cycle distribution for Hep3B cells treated with 5-FU. A, 5-FU 20 μg/ml. B, 5-FU
50 μg/ml. Data are mean of three separate experiments.
Fig. 6. Effect of tBid in combination with 5-FU on apoptosis of Hep3B cells. Cells were
treated with 200 nM tBid in combination with 50 μg/ml 5-FU or either agent alone for
24 h. Apoptosis was determined by TUNEL assay. A, The proportion of the apoptotic
cells was shown. The vehicle-treated Hep3B cells were served as control. Data are the
mean±SE of three separate experiments. *Indicates pb0.05. B, Total protein was
isolated andWestern blot was used to detect tBid expression. Actin level was examined
and served as the loading control. Experiments were repeated twice. Bar graphs show
tBid expression normalized to actin (mean±SE, *pb0.05 vs. control).
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Several antitumor agents of different classes have been character-
ized in terms of the cell cycle phase speciﬁcity of induction of
apoptosis [1,2,25]. Most chemotherapeutic regimens combine drugs
targeting different phases of the cell cycle to increase the efﬁciency of
treatment. 5-FU may act throughout all phases of the cell cycle or at
some speciﬁc phases of the cell cycle depending on the types of cells
[5,6]. Previous studies indicated that the over-expression of Bid/tBid
could effectively induce cell death in HCC tumor cells [8,9]. In this
study, we evaluated susceptibility of Hep3B cells in deﬁned phases of
cell cycle to tBid.
We used two different methods to obtain synchronized fractions of
Hep3B. The ﬁrst one is to use cell cycle synchronization agents. AP can
arrest cells in S phase. AP is low cytotoxic and easy removal by washing
[26]. HY arrests cells in the early S phase [27]. ET synchronizes cells at
the G2/M boundary. In this study, the pharmacological doses of the
synchronization agents used did not generate signiﬁcant toxicity in the
cells (Supplementary Fig. S1), while they could effectively yield cell
cycle fractions with an acceptable degree of purity (Fig. 2). Our data are
in line with previous studies showing that cell cycle arrest induced by
serumstarvation or treatmentwithAPhad onlyminor effects on the cell
viability and did not abrogate the subsequent onset of apoptosis [28,29].
The dose of ET (0.2 μM) used was very low but it was enough to arrest
cells. It has been reported that 10 μM of ET needs to induce repairable
damage while 100 μM is usually used to induce apoptosis [30,31]. The
secondmethod used is to purify G1 phase cells by ﬂow sorting, which is
non-toxic and does not perturb the general apoptosis susceptibility of
the cells. This method yielded G1 fractions with a more acceptable
degree of purity (88%), compared with the result obtained using cell
cycle synchronization agents.
Previous studies have shown that cell cycle phase fractions of the
tumor tissues from HCC patients were G0/G1 (77.25%), S (6.17%), and
G2/M (16.62%), in contrast to cell cycle phase fraction of normal liver
G0/G1 (97.1%), S (2.1%), and G2/M (0.8%) [32,33]. In this study, the
time course progression revealed that tBid signiﬁcantly increased
Hep3B cell population of the G2/M phase and signiﬁcantly reduced
the percentage of G0/G1 phase. Activation of cdc2 and cyclin B1 is
essential to trigger G2/M phase transition [34]. Cdc2 is positively
regulated by the phosphorylation of Thr 161 and dephosphorylation
of Tyr 15 [35]. Although the levels of cyclin B1 and cdc2 p34 did not
show any signiﬁcant change in our Western blot analysis, the
expression of p-cdc2 p34 (Thr 161) was signiﬁcantly increased and
the level of p-cdc2 p34 (Tyr 15) was markedly decreased in the tBid-
treated cells compared with the control cells. At the same time, the
level of Cdk2 decreased, which is essential for cell cycle G1/S phase
transition. The levels of cyclin A and cyclin D1 were not signiﬁcantly
changed. Furthermore, tBid treatment caused activation of caspase 9
and caspase 3. Our experiment demonstrated that cells in G0/G1
phases were relatively more susceptible to tBid-induced cell death.
These results indicate that tBid may cause Hep3B cells arrest at the
G2/M phase of cell cycle and primarily induce the cells from the G0/G1
phase to apoptosis. This ﬁnding is in agreement with that Bid is
important for the accumulation of embryonic ﬁbroblast cells in the S
and G2/M phase of the cell cycle following ET-induced DNA damage
[31]. Bid can exhibit S phase checkpoint activation [15]. It may link
DNA repair processes and apoptosis, translating the cell damage into
either cell cycle arrest (at low levels of damage) or apoptosis (at high
levels of damage) [31]. Therefore, DNA repair and cell cycle
checkpoint pathways allow cells to deal with damages. The G2/M
checkpoint prevents cells from initiating mitosis when they progress
into G2/M with some unrepaired damage inﬂicted during previous S
or G0/G1 phases [36,37]. These cellular responses are important for
determining responses to current cancer therapies.
It has been reported that G2/M arrest occurs in response to many
types of DNA damages. Hep3B cells used in this study were p53
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accumulate in G2/M after tBid treatment indicates that p53-
independent mechanisms are sufﬁcient to sustain the G2/M arrest.
At the same time, this phenomenon has inspired efforts to manipulate
or regulate the G2/M checkpoint as a potential strategy to improve the
efﬁciency of cytotoxic drugs and sensitize cancer cells to radiation or
chemotherapeutic agents [38,39]. Fortunately, we found that 5-FU
signiﬁcantly reduced Hep3B cells in G2/M phase, while mainly
increased cells in the G0/G1 phase. The high percentage of tumor
cells staying in the G0/G1 phase is known to contribute to resistance
to 5-FU [40]. Our ﬁnding indicates that tBid mainly target the tumor
cells in the G0/G1 phase. Therefore, tBid and 5-FU in combinationmay
maximize their antitumor effect by targeting tumor cells in the
different phases of the cell cycle. Such a complementary effect of tBid
and 5-FU on different phases of the cell cycle may partly explain the
synergetic therapeutic results when tBid is used in combination with
5-FU to treat HCC cells in our previous studies [8,9] and in this study.
Our present ﬁndings thus provide useful information for the
optimization of tBid and other antitumor agents in combination to
inhibit tumor growth. It remains highly interesting to test how the
combination of tBid with other chemotherapeutic agents will affect
the tumor cell survival.
In conclusion, this study showed that tBid may play roles in the
interplay between apoptosis and cell cycle regulation. The elucidation
of phase-speciﬁc effect of tBid points to a possible therapeutic option
that combines different phase-speciﬁc agents to overcome resistance
of HCC and treat HCC more effectively.
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